Fania Samuels, MD
Clinical Cardiac Electrophysiology · Philadelphia, PANPI 1255305017
Payments from drug & device makers
Across 492 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$943
- Pfizer$772
- Amarin Pharma, Inc.$744
- Sanofi-aventis U.S. LLC$732
- AstraZeneca$598
- Merck$596
- plus $4K from 31 others
What the payments were for
- Food & beverage$8,705100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 46 | $943 |
| Pfizer | 52 | $772 |
| Amarin Pharma, Inc. | 49 | $744 |
| Sanofi-aventis U.S. LLC | 40 | $732 |
| AstraZeneca | 35 | $598 |
| Merck | 32 | $596 |
| Boehringer Ingelheim | 31 | $566 |
| Johnson & Johnson | 29 | $496 |
| Novartis | 28 | $462 |
| Boston Scientific | 15 | $379 |
| Impulse Dynamics (USA) Inc. | 11 | $306 |
| Kowa Pharmaceuticals America, Inc. | 20 | $244 |
| E.r. Squibb & Sons, L.L.C. | 16 | $214 |
| Esperion Therapeutics, Inc. | 12 | $198 |
| Lexicon Pharmaceuticals, Inc. | 6 | $171 |
| Scpharmaceuticals Inc. | 10 | $168 |
| Bayer | 7 | $135 |
| Astellas Pharma US Inc | 6 | $99 |
| Gilead | 7 | $98 |
| Edwards Lifesciences | 4 | $76 |
| Biogen | 3 | $75 |
| Biosense Webster, Inc. | 2 | $67 |
| Regeneron Healthcare Solutions, Inc. | 4 | $66 |
| Althera Pharmaceuticals LLC | 3 | $66 |
| Alnylam Pharmaceuticals Inc. | 3 | $62 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $56 |
| Agepha Pharma FZ LLC | 3 | $49 |
| Medicomp Inc | 2 | $38 |
| Medtronic | 2 | $37 |
| Abbott | 2 | $35 |
| Bardy Diagnostics, Inc. | 2 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $29 |
| Corcept Therapeutics | 1 | $29 |
| Kestra Medical Technology Services, Inc. | 1 | $25 |
| Irhythm Technologies, Inc. | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $13 |
How this compares
$8,716 in reported general payments places this provider in the 25th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
See all clinical cardiac electrophysiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 563 | $420,378 |
| VascepaIcosapent Ethyl | 427 | $180,102 |
| XareltoRivaroxaban | 192 | $160,586 |
| EntrestoSacubitril/Valsartan | 171 | $143,569 |
| MultaqDronedarone Hcl | 143 | $122,136 |
| Repatha SureclickEvolocumab | 148 | $95,756 |
| FarxigaDapagliflozin Propanediol | 123 | $87,988 |
| Icosapent Ethyl | 167 | $42,861 |
| Praluent PenAlirocumab | 57 | $31,521 |
| JardianceEmpagliflozin | 23 | $23,411 |
| Rosuvastatin Calcium | 1,861 | $16,530 |
| LivaloPitavastatin Calcium | 33 | $12,781 |
| Ranolazine ErRanolazine | 155 | $10,885 |
| Losartan Potassium | 983 | $7,059 |
| Doxazosin Mesylate | 621 | $5,372 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $772 | $420,378563 claims |
| Johnson & JohnsonXarelto | $496 | $160,586192 claims |
| NovartisEntresto | $462 | $143,569171 claims |
| Sanofi-aventis U.S. LLCMultaq | $732 | $122,136143 claims |
| AstraZenecaFarxiga | $598 | $87,988123 claims |
| Boehringer IngelheimJardiance | $566 | $23,41123 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $244 | $12,78133 claims |
| Esperion Therapeutics, Inc.Nexletol | $198 | $4,80512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.
Other clinical cardiac electrophysiology in Philadelphia
- Pasquale SantangeliPhiladelphia$1.3M
- Francis MarchlinskiPhiladelphia$1.2M
- David FrankelPhiladelphia$722K
- Fermin GarciaPhiladelphia$713K
- Timothy MarkmanPhiladelphia$693K
- Ralph VerdinoPhiladelphia$682K
- Robert SchallerPhiladelphia$579K
- Rajat DeoPhiladelphia$519K
- Matthew HymanPhiladelphia$474K
- Joshua CooperPhiladelphia$405K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.